Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor

Details for Australian Patent Application No. 2005228426 (hide)

Owner North Shore-Long Island Jewish Research Institute

Inventors Al-Abed, Yousef

Agent Shelston IP

Pub. Number AU-B-2005228426

PCT Pub. Number WO2005/094338

Priority 60/557,169 29.03.04 US

Filing date 29 March 2005

Wipo publication date 13 October 2005

Acceptance publication date 15 July 2010

International Classifications

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/094338 Priority application(s): WO2005/094338

15 July 2010 Application Accepted

  Published as AU-B-2005228426

11 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005228434-Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand

2005228421-Multi-vitamin and mineral nutritional supplements